The Food and Drug Administration (FDA) lifted the black box warning from hormone replacement therapies late last year, leading to a surge in demand for estrogen patches. As a result, these patches have become difficult to obtain due to their rising popularity. Despite reports of shortages from doctors and patients, the FDA has not classified any estrogen patches as being in short supply. FDA chief Dr. Marty Makary indicated that while demand has increased significantly, manufacturers are working to adjust their production and distribution systems to meet it. The American Society of Health-System Pharmacists has listed 14 brands or dosages of estrogen patches as being in shortage since January, although some companies report no issues fulfilling prescriptions.
Why It Matters
The increase in estrogen patch demand can be traced back to the historical narratives surrounding hormone therapy, particularly after the 2002 Women’s Health Initiative study, which linked these treatments to various health risks. Prescriptions for estrogen-based therapies among women aged 45 to 54 surged by 184% from 2018 to 2026, reflecting a significant shift in perception and utilization of these therapies. The FDA’s removal of the black box warning likely influenced this renewed interest, highlighting the evolving understanding of hormone replacement therapy’s benefits and risks. As the healthcare landscape changes, tracking and addressing drug supply issues remains critical for patient care.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
